Article
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Investigational new drugs - 1 Dec 2014
Bowles Daniel W, Senzer Neil, Hausman Diana, Peterson Scott, Vo Alex, Walker Luke, Cohen Roger B, Jimeno Antonio
Abstract excerpt
BACKGROUND: This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), and antitumor activity of PX-866, a phosphatidylinositol 3-kinase inhibitor, combined with cetuximab in patients with incurable colorectal cancer or squamous cell carc...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.